The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

CompanyOverview\|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

Moderna has been utilizing its messenger-RNA technology on personalized cancer vaccines. Its mRNA-4157, in collaboration with Merck & Co. MRK and its blockbuster Keytruda, has proven to cut ...

a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...

President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...

The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the ...